Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today ...
Tonix remains rated Hold as Tonmya's commercial launch underwhelms, with Q1 2026 net product revenue at $3.7m. Read more on ...
IREN (IREN) has been added to the Russell 1000 Index as the Russell U.S. Indexes shift from an annual to a semi-annual ...
SGLT2 inhibitor use also correlated with lower rates of psychiatric ED visits ...